Key result
Coronary revascularization in ICB-myocarditis is linked to ~4-fold higher 90-day myocarditis-related mortality.
Why the study?
Immune checkpoint blocker myocarditis may overlap with acute coronary syndrome, complicating prompt clinical diagnosis and management in patients with coronary artery disease.
Does coronary revascularization impact 90-day mortality in patients with immune checkpoint blocker myocarditis and concomitant coronary artery disease?
Cohort (n=261)
Yes
Does coronary revascularization impact 90-day mortality in patients with immune checkpoint blocker myocarditis and concomitant coronary artery disease?
In patients with ICB-myocarditis, concomitant CAD is common, and undergoing coronary revascularization is associated with higher 90-day myocarditis-related mortality, potentially due to delayed diagnosis and delayed steroid administration.
Answers are grounded in this paper and cite their sources.
Revascularization warrants caution in ICB-myocarditis with CAD; leaves open whether it delays steroids or marks sicker patients.
PURPOSE: Immune checkpoint blocker (ICB) associated myocarditis (ICB-myocarditis) may present similarly and/or overlap with other cardiac pathology including acute coronary syndrome presenting a challenge for prompt clinical diagnosis. METHODS: An international registry was used to retrospectively identify cases of ICB-myocarditis. Presence of coronary artery disease (CAD) was defined as coronary artery stenosis >70% in patients undergoing coronary angiogram. RESULTS: Among 261 patients with clinically suspected ICB-myocarditis who underwent a coronary angiography, CAD was present in 59/261 patients (22.6%). Coronary revascularization was performed during the index hospitalisation in 19/59 (32.2%) patients. Patients undergoing coronary revascularization less frequently received steroids administration within 24 h of admission compared to the other groups (p = 0.029). Myocarditis-related 90-day mortality was 9/17 (52.7%) in the revascularised cohort, compared to 5/31 (16.1%) in those not revascularized and 25/156 (16.0%) in those without CAD (p = 0.001). Immune-related adverse event-related 90-day mortality was 9/17 (52.7%) in the revascularized cohort, compared to 6/31 (19.4%) in those not revascularized and 31/156 (19.9%) in no CAD groups (p = 0.007). All-cause 90-day mortality was 11/17 (64.7%) in the revascularized cohort, compared to 13/31 (41.9%) in no revascularization and 60/158 (38.0%) in no CAD groups (p = 0.10). After adjustment of age and sex, coronary revascularization remained associated with ICB-myocarditis-related death at 90 days (hazard ratio [HR] = 4.03, 95% confidence interval [CI] 1.84-8.84, p < 0.001) and was marginally associated with all-cause death (HR = 1.88, 95% CI, 0.98-3.61, p = 0.057). CONCLUSION: CAD may exist concomitantly with ICB-myocarditis and may portend a poorer outcome when revascularization is performed. This is potentially mediated through delayed diagnosis and treatment or more severe presentation of ICB-myocarditis.
No takes yet. Share an insight, caveat, or question.
Nowatzke et al. (2022) conducted a cohort in Immune checkpoint blocker (ICB) associated myocarditis (n=261). Coronary revascularization vs. No revascularization was evaluated on ICB-myocarditis-related death at 90 days (HR 4.03, 95% CI 1.84-8.84, p=<0.001). Coronary revascularization in patients with ICB-myocarditis was associated with increased 90-day myocarditis-related mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: